The recent expansion of the topical ruxolitinib approval to include pediatric patients aged 2 to 11 years with atopic dermatitis (AD) provides the first JAK inhibitor therapy option for this young population. In this episode, "Management of Atopic Dermatitis with JAK Inhibitors: A Pediatric to Geriatric Perspective," expert dermatologists, Christopher Bunick, MD, PhD and Karan Lal, DO discuss:

1. Importance of JAK/STAT signaling in AD and the role of JAK inhibition in the future of dermatology

2. Long-term safety of topical therapies for chronic AD

3. Topline efficacy safety data from the phase 3 TRuE-AD3 clinical trial

4. Shifting the paradigm of topical AD care across patient populations